alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>                    This schedule contains summary financial information
extracted  from  the  Company's  Balance  Sheet  at  December  31,  1997 and the
Company's Statement of Income for the Nine Months Ended December 31, 1997 and is
qualified in its entirety by reference to such financial statements.                     
</LEGEND>
                 
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              MAR-31-1998
<PERIOD-START>                                 APR-01-1997
<PERIOD-END>                                   DEC-31-1997
<CASH>                                         9,378,460
<SECURITIES>                                   0
<RECEIVABLES>                                  16,897,249
<ALLOWANCES>                                   0
<INVENTORY>                                    16,446,844
<CURRENT-ASSETS>                               44,295,219
<PP&E>                                         12,254,501
<DEPRECIATION>                                 0
<TOTAL-ASSETS>                                 59,910,380
<CURRENT-LIABILITIES>                          14,073,048
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    2,410
<COMMON>                                       121,178
<OTHER-SE>                                     0
<TOTAL-LIABILITY-AND-EQUITY>                   59,910,380
<SALES>                                        68,525,787
<TOTAL-REVENUES>                               0
<CGS>                                          0
<TOTAL-COSTS>                                  39,590,928
<OTHER-EXPENSES>                               18,259,917
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             327,885
<INCOME-PRETAX>                                10,347,057
<INCOME-TAX>                                   3,560,672
<INCOME-CONTINUING>                            6,786,385
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   6,786,385
<EPS-PRIMARY>                                  .54
<EPS-DILUTED>                                  .52
        


</TABLE>
<PAGE>
                                                                    EXHIBIT 99.1




                   K-V PHARMACEUTICAL COMPANY AND SUBSIDIARIES


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of K-V Pharmaceutical Company (the
"Company") on Form 10-Q for the period ending June 30, 2002 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Marc S.
Hermelin, Vice Chairman and Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

        (1)   The Report fully complies with the requirements of section 13(a)
              or 15(d) of the Securities Exchange Act of 1934; and

        (2)   The information contained in the Report fairly presents, in all
              material respects, the financial condition and result of
              operations of the Company.



/s/  MARC S. HERMELIN
-----------------------------------------
Marc S. Hermelin
Vice Chairman and Chief Executive Officer
August 9, 2002
#### IN RE ODOM

No. 178P82.

Case below: 56 N.C. App. 412.

Petition by F. L. Odom, Jr. for writ of certiorari to North Carolina Court of Appeals denied 2 June 1982.
[Federal Register Volume 72, Number 202 (Friday, October 19, 2007)]
[Notices]
[Page 59258]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-5182]


-----------------------------------------------------------------------

COMMODITY FUTURES TRADING COMMISSION


Sunshine Act Meetings

Time and Date: 2 p.m., Wednesday, November 28, 2007.

Place: 1155 21st St., NW., Washington, DC, 9th Floor Commission 
Conference Room.

Status: Closed.

Matters to be Considered: Enforcement Matters.

Contact Person for More Information:  Sauntia S. Warfield, 202-418-
5084.

David A. Stawick,
Secretary of the Commission.
[FR Doc. 07-5182 Filed 10-16-07; 4:41 pm]
BILLING CODE 6351-01-M
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Commerce

###### Bureau of Industry and Security

The Materials Technical Advisory Committee will meet on December 8, 2005, 10:30 a.m., Herbert C. Hoover Building, Room B841A, 14th Street between Constitution & Pennsylvania Avenues, NW., Washington, DC. The Committee advises the Office of the Assistant Secretary for Export Administration with respect to technical questions that affect the level of export controls applicable to materials and related technology.

## Agenda

### Public Session

1. Opening remarks and introductions.

2. Presentation by Boeing.

### Closed Session

3. Discussion of matters determined to be exempt from the provisions relating to public meetings found in 5 U.S.C. app. 2 sections 10(a)(1) and 10(a)(3).

                    A limited number of seats will be available during the public session of the meeting. Reservations are not accepted. To the extent time permits, members of the public may present oral statements to the Committee. Written statements may be submitted at any time before or after the meeting. However, to facilitate distribution of public presentation materials to Committee members, the materials should be forwarded prior to the meeting to Ms. Yvette Springer at                     *Yspringer@bis.doc.gov.*

The Assistant Secretary for Administration, with the concurrence of the delegate of the General Counsel, formally determined on November 18, 2005, pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, that the portion of the meeting dealing with matters the premature disclosure of which would likely frustrate the implementation of a proposed agency action as described in 5 U.S.C. 552b(c)(9)(B) shall be exempt from the provisions relating to public meetings found in 5 U.S.C. app. 2 sections  10(a)(1) and 10(a)(3). The remaining portions of the meeting will be open to the public.

For more information, call Yvette Springer at (202) 482-4814.

Dated: November 28, 2005.

Yvette Springer,

Committee Liaison Officer.

[FR Doc. 05-23535 Filed 11-30-05; 8:45 am]

BILLING CODE 3510-JT-M
Case 1:06-cr-00518-SHS Document 97 Filed 07/15/2008 Page 1 of 1
---

|CERTIFICATION                                
|---------------------------------------------
|PURSUANT TO                                  
|18 U.S.C. SECTION 1350,                      
|AS ADOPTED PURSUANT TO                       
|SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, John Bristow, Chief Executive Officer of Rockwell Diamonds
Inc. (the Company), hereby certify pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the
best of my knowledge:

(1) The Annual Report on Form 40-F of
the Company for the fiscal year ended February 29, 2008 (the Annual Report)
fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended; and

(2) The information contained in the
Annual Report fairly presents, in all material respects, the financial condition
and results of operations of the Company.

| | By:    | /s/ J. Bristow         
| | ------ | -----------------------
| |        |                        
| | Name:  | John Bristow           
| | Title: | Chief Executive Officer
| |        |                        
| | Date:  | May 28, 2008           

This written statement is being furnished to the Securities
and Exchange Commission as an exhibit to the Companys Annual Report on Form
40-F. A signed original of this statement has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.

This certification accompanies this Annual Report on Form
40-F pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not,
except to the extent required by such Act, be deemed filed by the Company for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act). Such certification will not be deemed to be incorporated by
reference into any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except to the extent that the Company specifically incorporates it
by reference.

---
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 1 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 2 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 3 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 4 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 5 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 6 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 7 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 8 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 9 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 10 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 11 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 12 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 13 of 14
Case 1:07-cv-03580-DLC Document 31 Filed 06/15/2007 Page 14 of 14
#### STATE v. ANDERSON

No. 420P82.

Case below: 57 N.C. App. 602.

Petition by defendants for discretionary review under G.S. 7A-31 denied 25 August 1982.
### IN THE TENTH COURT OF APPEALS No. 10 - 15 - 00043 - CR BRENDA ELAINE PATTER SON , Appellant v. THE STATE OF TEXAS , Appellee

From the 220th District Court Hamilton County, Texas Trial Court No. CR - 07999 MEMORANDUM OPINION On February 12, 2015, Appellant Brenda Patterson filed a notice of appeal that included both Trial Court Cause Nos. CR07998 and CR07999. The appeals were docketed as Appellate Court Cause Nos. 10

- 15
- 00042
- CR and 10

- 15
- 00043
- CR, respectively. The trial co urt clerk informed the Court, however, that there is no appealable order or judgment in the record in Trial Court Cause No. CR07999 (Appellate Co urt Cause No. 10

- 15
- 00043
- CR).Patterson v. State Page 2

In the Clerk of the Court’s February 25, 2015 letter, Patterson was warned that the Court would dismiss Appellate Court Cause No. 10

- 15
- 00043
- CR because there is no appealable order or judgment in the record unless, within fourteen day s after the date of the letter, Patterson showed grounds for continuing the appeal. The letter was s ent to Patterson’s appointed trial counsel, who had filed the notice of appeal. Patterson’s appellate counsel has now filed a motion to dismiss this appeal for lack of jurisdiction, acknowledging that no judgment or other appealable order has been rendere d in Trial Court Cause No. CR07999 (Appellate Court Cause No. 10

- 15
- 00043
- CR)
. We therefore grant the motion to dismiss and dismiss this appeal for want of jurisdiction because there is no appealable order or judgment in the record. See McKown v. Stat e , 915 S.W.2d 160, 161 (Tex. App.

— Fort Worth 1996, no pet.).

REX D. DAVIS Justice Before Chief Justice Gray, Justice Davis, and Justice Scoggins Appeal dismissed Opinion delivered and filed March 26, 2015 Do not publish [C R25]
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

§

ANGELA AMATO

, No. 08

- 18

- 00 224

- CR

§

Appeal from the

APPELLANT

, §

409th District Court

V. §

of El Paso County, Texas

THE STATE OF TEXAS, §

(TC# 20150D02835 )

APPELLEE

. §

MEMORANDUM OPINION

Appellant, Angela Amato

, has filed a motion to dismiss h er appeal pursuant to Rule 42.2.

This rule permits an appellate court to dismiss a criminal appeal on the appellant's moti on at any

time before the court’ s decision. T EX .R.A PP .P. 42.2(a). Finding that Appellant's motion complies

with the requirements of Rule 42.2(a), we grant the motion and dismiss the appeal.

April 24, 2019

YVONNE T. RODRIGUEZ, Justice

Before McClure, C.J., Rodriguez, and Palafox, JJ.

(Do Not Publish)
<TABLE> <S> <C>

                  <S>        <C>
<ARTICLE> 5
<S>                                                        <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END>                                          JUL-31-2000
<PERIOD-START>                                             AUG-01-1999
<PERIOD-END>                                               APR-30-2000
<CASH>                                                           94656
<SECURITIES>                                                         0
<RECEIVABLES>                                                    54298
<ALLOWANCES>                                                         0
<INVENTORY>                                                          0
<CURRENT-ASSETS>                                                269943
<PP&E>                                                         3476941
<DEPRECIATION>                                                  153582
<TOTAL-ASSETS>                                                 3323359
<CURRENT-LIABILITIES>                                           541537
<BONDS>                                                         883387
<PREFERRED-MANDATORY>                                                0
<PREFERRED>                                                          0
<COMMON>                                                       1879898
<OTHER-SE>                                                      473985
<TOTAL-LIABILITY-AND-EQUITY>                                   3778808
<SALES>                                                              0
<TOTAL-REVENUES>                                                196449
<CGS>                                                                0
<TOTAL-COSTS>                                                   479822
<OTHER-EXPENSES>                                                     0
<LOSS-PROVISION>                                                     0
<INTEREST-EXPENSE>                                               (6836)
<INCOME-PRETAX>                                                (254654)
<INCOME-TAX>                                                    106349
<INCOME-CONTINUING>                                             (148305)
<DISCONTINUED>                                                       0
<EXTRAORDINARY>                                                      0
<CHANGES>                                                            0
<NET-INCOME>                                                   (148305)
<EPS-BASIC>                                                   (18.60)
<EPS-DILUTED>                                                   (18.60)


</TABLE>
[Federal Register Volume 70, Number 234 (Wednesday, December 7, 2005)]
[Notices]
[Page 72844]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-23675]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Industry Exchange Workshop on Food and Drug Administration 
Clinical Trial Requirements; Public Workshop; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of public workshop on FDA clinical trial 
statutory and regulatory requirements. This workshop was announced in 
the Federal Register of September 21, 2005 (70 FR 55405). The amendment 
is made to reflect a change in the Location portion of the document. 
There are no other changes.

FOR FURTHER INFORMATION CONTACT:  David Arvelo, Food and Drug 
Administration, 4040 North Central Expressway, suite 900, Dallas TX 
75204, 214-253-4952, FAX: 214-253-4970, e-mail: <a href="/cdn-cgi/l/email-protection#234c5142505451504151634c51420d4547420d444c55"><span class="__cf_email__" data-cfemail="305f4251434742435242705f42511e5654511e575f46">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: In the Federal Register of September 21, 
2005 (70 FR 55405), FDA announced that a public workshop entitled 
``Industry Exchange Workshop on Food and Drug Administration Clinical 
Trial Requirements'' would be held on Wednesday, February 8, 2006. On 
page 55405, in the first column, the Location portion of the document 
is amended to read as follows:
    Location: The public workshop will be held at the Renaissance 
Houston Hotel Greenway Plaza, 6 Greenway Plaza East, Houston, TX 77046, 
713-629-1200, FAX: 713-629-4702.

    Dated: November 30, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-23675 Filed 12-6-05; 8:45 am]
BILLING CODE 4160-01-S


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Reduce your dust exposure

Spraying or hosing cleanup

Did you know?

Starting with a forceful stream of water 

during housekeeping (e.g., hosing down 

equipment, walls, beams, and the floor) 

can elevate dust exposure

During housekeeping, 

begin with a wide spray 

to wet everything down

Then use a narrow, 

forceful stream

Findings based on NIOSH field studies

To learn more, visit go.usa.gov/xRkXu

Centers for Disease Control

and Prevention

National Institute for Occupational

Safety and Health
#### CAROLINAS-VIRGINIAS ASSOC. v. INGRAM, COMR. OF INSURANCE

No. 67 PC.

Case below: 39 N.C. App. 688.

Petition by defendants for discretionary review under G.S. 7A-31 denied 1 May 1979.
<PAGE>

                                                                   EXHIBIT 10.2


                                  STRAIGHT NOTE


         $200,000          South El Monte, California         June 28, 1999


     For value received, Lee Pharmaceuticals promises to pay Mark DiSalvo or
order, at South El Monte, California the sum of TWO HUNDRED THOUSAND DOLLARS,
with interest from June 28, 1999, on unpaid principal at the rate of twenty (20)
per cent per annum; principal is payable monthly, commencing on August 15, 1999,
with monthly principal payments of $10,000. Interest shall be calculated on the
basis of the unpaid principal balance daily, based on a 365 day year, actual day
month, payable monthly. Principal and interest shall be payable in lawful money
of the United States. If action be instituted on this note, I promise to pay
such sum as the Court may fix as attorney's fees. This note is secured by the
following trademarks; Aloe E, Aloe 99, Amitone, Aquafilter, Baby Gasz, Baby
Gumz, Beau Kreml, Bikini Bare, Breath-Gard, Brush'n Floss, Cheracol, Creamalin,
Creo-Terpin, Dentlock, Dr. Hands, Evac-U-Gen, Femiron, iodex Klutch, Liquiprin,
Peterson's Ointment, Pristeen, Rose Milk, Saxon, Stop'n Grow, Sundance,
TearGard, ThexForte, Venture, and Zonite.



        June 30, 1999                               RONALD G. LEE
        -------------                 ----------------------------------------
        Date                          Lee Pharmaceuticals -- Ronald G. Lee





        June 30, 1999                             MICHAEL L. AGRESTI
        -------------                 -----------------------------------------
        Date                          Lee Pharmaceuticals -- Michael L. Agresti
<TABLE> <S> <C>

<ARTICLE> 7
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF THE LIBERTY CORPORATION FOR THE YEAR ENDED
DECEMBER 31, 1996, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-31-1996
<DEBT-HELD-FOR-SALE>                         1,517,539
<DEBT-CARRYING-VALUE>                                0
<DEBT-MARKET-VALUE>                                  0
<EQUITIES>                                      75,791
<MORTGAGE>                                     230,910
<REAL-ESTATE>                                  132,696
<TOTAL-INVEST>                               2,078,272
<CASH>                                          36,774
<RECOVER-REINSURE>                             277,578
<DEFERRED-ACQUISITION>                         262,182
<TOTAL-ASSETS>                               3,060,765
<POLICY-LOSSES>                              1,853,173
<UNEARNED-PREMIUMS>                                  0
<POLICY-OTHER>                                  31,450
<POLICY-HOLDER-FUNDS>                           28,488
<NOTES-PAYABLE>                                247,861
<PREFERRED-MANDATORY>                           45,599
<PREFERRED>                                     20,999
<COMMON>                                       163,443
<OTHER-SE>                                     396,419
<TOTAL-LIABILITY-AND-EQUITY>                 3,060,765
<PREMIUMS>                                     321,371
<INVESTMENT-INCOME>                            155,221
<INVESTMENT-GAINS>                              (2,582)
<OTHER-INCOME>                                 145,087
<BENEFITS>                                     218,751
<UNDERWRITING-AMORTIZATION>                     73,967
<UNDERWRITING-OTHER>                           140,273
<INCOME-PRETAX>                                 56,499
<INCOME-TAX>                                    19,159
<INCOME-CONTINUING>                             37,340
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    37,340
<EPS-PRIMARY>                                     1.67
<EPS-DILUTED>                                     1.66
<RESERVE-OPEN>                                       0
<PROVISION-CURRENT>                                  0
<PROVISION-PRIOR>                                    0
<PAYMENTS-CURRENT>                                   0
<PAYMENTS-PRIOR>                                     0
<RESERVE-CLOSE>                                      0
<CUMULATIVE-DEFICIENCY>                              0
        

</TABLE>